The tuberous sclerosis complex

被引:307
作者
Orlova, Ksenia A.
Crino, Peter B. [1 ]
机构
[1] Univ Penn, Med Ctr, Dept Neurol, Sch Med, Philadelphia, PA 19104 USA
来源
YEAR IN NEUROLOGY 2 | 2010年 / 1184卷
关键词
tuberous sclerosis complex (TSC); focal cortical malformations (FCMs); TSC1; genes; TSC2; rapamycin; EKER RAT MODEL; RIBOSOMAL-PROTEIN S6; LINE TSC2 MUTATION; GIANT-CELL TUMORS; MAMMALIAN TARGET; GENE-PRODUCT; EMBRYONIC LETHALITY; CORTICAL DYSPLASIA; ACTIN CYTOSKELETON; MISSENSE MUTATIONS;
D O I
10.1111/j.1749-6632.2009.05117.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder that results from mutations in the TSC1 or TSC2 genes and is associated with hamartoma formation in multiple organ systems. The neurological manifestations of TSC are particularly challenging and include infantile spasms, intractable epilepsy, cognitive disabilities, and autism. Progress over the past 15 years has demonstrated that the TSC1 or TSC2 encoded proteins modulate cell function via the mTOR signaling cascade and serve as keystones in regulating cell growth and proliferation. The mTOR pathway provides an intersection for an intricate network of protein cascades that respond to cellular nutrition, energy levels, and growth-factor stimulation. In the brain, TSC1 and TSC2 have been implicated in cell body size, dendritic arborization, axonal outgrowth and targeting, neuronal migration, cortical lamination, and spine formation. Antagonism of the mTOR pathway with rapamycin and related compounds may provide new therapeutic options for TSC patients.
引用
收藏
页码:87 / 105
页数:19
相关论文
共 159 条
[1]  
Andermann F, 2000, ADV NEUROL, V84, P479
[2]   Classics in brachytherapy: Margaret Cleaves introduces gynecologic brachytherapy [J].
Aronowitz, Jesse N. ;
Aronowitz, Shoshana V. ;
Robison, Roger F. .
BRACHYTHERAPY, 2007, 6 (04) :293-297
[3]   Hamartin, the tuberous sclerosis complex 1 gene product, interacts with polo-like kinase 1 in a phosphorylation-dependent manner [J].
Astrinidis, A ;
Senapedis, W ;
Henske, EP .
HUMAN MOLECULAR GENETICS, 2006, 15 (02) :287-297
[4]   Cell cycle-regulated phosphorylation of hamartin, the product of the tuberous sclerosis complex 1 gene, by cyclin-dependent kinase 1 cyclin B [J].
Astrinidis, A ;
Senapedis, W ;
Coleman, TR ;
Henske, EP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (51) :51372-51379
[5]   Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38 [J].
Bai, Xiaochun ;
Ma, Dongzhu ;
Liu, Anling ;
Shen, Xiaoyun ;
Wang, Qiming J. ;
Liu, Yongjian ;
Jiang, Yu .
SCIENCE, 2007, 318 (5852) :977-980
[6]   LKB1 and SAD kinases define a pathway required for the polarization of cortical neurons [J].
Barnes, Anthony P. ;
Lilley, Brendan N. ;
Pan, Y. Albert ;
Plummer, Lisa J. ;
Powell, Ashton W. ;
Raines, Alexander N. ;
Sanes, Joshua R. ;
Polleux, Franck .
CELL, 2007, 129 (03) :549-563
[7]   mTOR cascade activation distinguishes tubers from focal cortical dysplasia [J].
Baybis, M ;
Yu, J ;
Lee, A ;
Golden, JA ;
Weiner, H ;
McKhann, G ;
Aronica, E ;
Crino, PB .
ANNALS OF NEUROLOGY, 2004, 56 (04) :478-487
[8]   The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination [J].
Benvenuto, G ;
Li, SW ;
Brown, SJ ;
Braverman, R ;
Vass, WC ;
Cheadle, JP ;
Halley, DJJ ;
Sampson, JR ;
Wienecke, R ;
DeClue, JE .
ONCOGENE, 2000, 19 (54) :6306-6316
[9]   The death-associated protein kinases: Structure, function, and beyond [J].
Bialik, Shani ;
Kimchi, Adi .
ANNUAL REVIEW OF BIOCHEMISTRY, 2006, 75 :189-210
[10]   Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis [J].
Bissler, John J. ;
McCormack, Francis X. ;
Young, Lisa R. ;
Elwing, Jean M. ;
Chuck, Gail ;
Leonard, Jennifer M. ;
Schmithorst, Vincent J. ;
Laor, Tal ;
Brody, Alan S. ;
Bean, Judy ;
Salisbury, Shelia ;
Franz, David N. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (02) :140-151